OncoCyte Corp (NASDAQ:OCX)
| 0.8631 Delayed Data As of Aug 09 |  -0.0866 / -9.12%Today’s Change | 0.81 Today|||52-Week Range 5.48 | -60.23% Year-to-Date |
Latest OCX News | Press Releases
| Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates Aug 08 / Zacks.com - Paid Partner Content | Icon PLC (ICLR) Tops Q2 Earnings and Revenue Estimates Jul 27 / Zacks.com - Paid Partner Content |
| Sotera Health Company (SHC) Tops Q2 Earnings and Revenue Estimates Aug 04 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 0.95 |
| Today’s open | 0.91 |
| Day’s range | 0.85 - 0.91 |
| Volume | 15,247 |
| Average volume (3 months) | 529,845 |
| Market cap | $116.9M |
Data as of 3:59pm ET, 08/09/2022
Growth & Valuation
| Earnings growth (last year) | -57.69% |
| Earnings growth (this year) | +33.53% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +535.44% |
| P/E ratio | NM |
| Price/Sales | 24.97 |
| Price/Book | 1.39 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CAPRCapricor Therapeutic... | +0.10 | +2.32% |
| --Evolva Holding SA | 0.00 | 0.00% |
| MNOVMediciNova Inc | 0.00 | 0.00% |
| DAREDare Bioscience Inc | -0.02 | -1.60% |
Data as of 3:59pm ET, 08/09/2022
Financials
| Next reporting date | August 11, 2022 |
| EPS forecast (this quarter) | -$0.12 |
| Annual revenue (last year) | $7.7M |
| Annual profit (last year) | -$64.1M |
| Net profit margin | -829.52% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Irvine, California |
Forecasts
